Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Product Performance, Big Money Lift Exelixis
06:25am, Friday, 23'rd May 2025
Shares of Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, boosted by Big Money inflows.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
04:05pm, Thursday, 22'nd May 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cow
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?
01:06pm, Monday, 19'th May 2025
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects
10:16am, Monday, 19'th May 2025
Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
10:50am, Thursday, 15'th May 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis: A Notable Quarter
02:53pm, Wednesday, 14'th May 2025
Exelixis just delivered a strong Q1 beat, raised 2025 guidance, and continues to benefit from robust Cabometyx sales and share buybacks. The company is transitioning to zanzalintinib as its next flags
Why Exelixis Stock Is Skyrocketing Today
11:33am, Wednesday, 14'th May 2025
Shares of Exelixis (EXEL 17.92%) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday.
Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance
10:44am, Wednesday, 14'th May 2025
Exelixis Inc. EXEL reported adjusted earnings of 62 cents per share on Tuesday for the first quarter of 2025, compared to 17 cents a year ago, beating the consensus of 36 cents.
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
10:01am, Wednesday, 14'th May 2025
Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.
Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript
08:31pm, Tuesday, 13'th May 2025
Exelixis, Inc. (NASDAQ:EXEL ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morr
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
07:01pm, Tuesday, 13'th May 2025
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street
Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates
06:20pm, Tuesday, 13'th May 2025
Exelixis (EXEL) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.17 per share a year ago.
MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixi
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
04:07pm, Tuesday, 13'th May 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives
